Investing in potentially the first cancer therapy to work in all tumours, irrespective of strain or mutation. 

LIfT Completed a major funding round in Jan 2022 and has a syndicate already being formed to take N-LIfT into the clinic for first-in-human trials in a range of solid tumours. If you are an institutional investor who would be interested in participating please email us

Proudly Supported by / Partnered with:

Merck kgaa logo.png
collaborate to Innovate logo.jpg
kizoo logo.png
EIT logo.png
BIA logo.png
Downing Ventures logo.png
KCL logo.png
meltwind logo.png

Note: This website contains certain statements that are not historical facts and may be forward-looking statements, please see our legal notices.